Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187096 · ClinicalTrials.gov registry record · NA
Natural Killer (NK) Cell Transplantation for AML
A NA study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT00187096: Completed NA study, sponsored by St. Jude Children's Research Hospital.
NCT00187096 is a NA study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00187096, a NA study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.
Primary Outcome
Document the number of patients experiencing grade 3 or 4 toxicities during conditioning and up to 100 days post-transplant. Toxicities were identified using Common Toxicity Criteria V 3.0 criteria.
Interventions
- DRUG Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2
- PROCEDURE Natural Killer Cell Infusion
- DEVICE CliniMACS System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2005-09 |
| Est. Completion | 2013-03 |
| Phase | NA |
What the finished NCT00187096 record still lists
NCT00187096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2 is the first listed.
NCT00187096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00187096 about?
NCT00187096 is a clinical study titled "Natural Killer (NK) Cell Transplantation for AML". The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.
What is the current status of trial NCT00187096?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2005-09. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00187096?
The interventions under investigation include: Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2 (DRUG), Natural Killer Cell Infusion (PROCEDURE), CliniMACS System (DEVICE).
Who is sponsoring clinical trial NCT00187096?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00187096's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia